Hemideina Successfully Raises $10m via Private Placement

Henslow acted as Lead Manager to raise $10m for Hemideina.

Hemideina is a Melbourne based, private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, The Hera Wireless Implant System.  The Company aims to provide a paradigm shift in hearing implant performance that will lead to increase access and adoption of treatment.

Founded in 2017 by Dr Kate Lomas and Dr Liz Williams, Hemideina aims to replicate normal human hearing more closely using their proprietary mechanical signal processing technology. Taking inspiration from nature, Hemideina’s approach to solving the challenge of severe-to-profound hearing loss will enable improved hearing quality, improved device utility and also provide aesthetic benefits for users.

The Hera Wireless Implant System comprises a sound processor/transmitter placed in the ear, a receiver/stimulator implanted in the mastoid cavity, and an electrode that stimulates the cochlea to provide the auditory cortex with sound information. Miniature and discreet, the device is designed to reduce the visible aesthetic usually associated with implanted hearing loss treatments.

The capital raised will be used to fund product development in preparation for first in human studies. Henslow has assisted Hemideina with fund raising since 2018. We are proud to support Hemideina on their mission to positively impact the lives of people with severe-to-profound hearing loss.

Want to discuss this transaction further?
Get in touch with the Henslow team below.

Recent posts

Looking for investment opportunities?

Backed and vetted by Henslow, unlock a selection of unique investment opportunities. Register an account to get started.

Investment hub